"Antibiotick\u00E1 profylaxe u hematoonkologick\u00FDch nemocn\u00FDch - doporu\u010Den\u00ED odborn\u00EDk\u016F s podporou CELL, \u010CHS a \u010COS \u010CSL JEP, S.CH.S SLS"@cs . . "Bakteri\u00E1ln\u00ED infekce jsou nej\u010Dast\u011Bj\u0161\u00ED \u017Eivot ohro\u017Euj\u00EDc\u00ED komplikac\u00ED u nemocn\u00FDch s febriln\u00ED neutropeni\u00ED po protin\u00E1dorov\u00E9 chemoterapii. Jedn\u00EDm z mo\u017En\u00FDch p\u0159\u00EDstup\u016F, jak sn\u00ED\u017Eit riziko bakteri\u00E9mie a \u00FAmrt\u00ED na sepsi v obdob\u00ED neutropenie, je antibakteri\u00E1ln\u00ED profylaxe antibiotiky. Randomizovan\u00E9 klinick\u00E9 studie srovn\u00E1vaj\u00EDc\u00ED profylaxi fluorochinolony proti placebu prok\u00E1zaly efekt profylaxe u nemocn\u00FDch s nejvy\u0161\u0161\u00EDm rizikem vzniku z\u00E1va\u017En\u00FDch infek\u010Dn\u00EDch komplikac\u00ED a \u00FAmrt\u00ED na n\u011B, tj. u nemocn\u00FDch s p\u0159edpokl\u00E1danou dlouhodobou a hlubokou absolutn\u00ED granulocytopeni\u00ED. Metaanal\u00FDzy t\u011Bchto studi\u00ED pak prok\u00E1zaly p\u0159\u00EDzniv\u00FD efekt profylaxe na pokles celkov\u00E9 mortality a mortality na infekci. Na z\u00E1klad\u011B t\u011Bchto studi\u00ED p\u0159edpokl\u00E1d\u00E1 skupina odborn\u00EDk\u016F CELL v kr\u00E1tk\u00E9m souhrnu doporu\u010Den\u00ED profylaxe fluorochinolony a sou\u010Dasn\u011B vyjad\u0159uje nutnost respektovat lok\u00E1n\u00ED epidemiologickou situaci jednotliv\u00FDch pracovi\u0161\u0165 p\u0159i vlastn\u00ED volb\u011B antibakteri\u00E1ln\u00ED profylaxe."@cs . "5" . . . . "4"^^ . . "Bacterial infections are potentially life-threatening complication in patients with febrile neutropenia (FN) after anticancer chemotherapy. Randomized controlled trials on fluoroquinolone (FQ) profilaxis provided the evidence of usefulness of such an approach in reducing the rate of febrile episodes, the rate of microbiologically documented infections, the rate of Gram-negative and Gram-positive infections, and meta-analyses proved the influence on reducing all-cause and infection-related mortality. Between the most risky patients (%22high risk%22),to whom prophylaxis brings the highest benefit, are those with expected long lasting and profound absolute granulocytopenia, seen mainly in patients with acute leukemia (AL) and in hematopoietic stem cell transplant (HSCT) recipients."@en . "Antibiotic profylaxis in hematooncological patients - expert recommendation with the support of CELL, CHS and COS CLS JEPO, S.CH.S. SLS"@en . . . "Kouba, Michal" . "Antibiotick\u00E1 profylaxe u hematoonkologick\u00FDch nemocn\u00FDch - doporu\u010Den\u00ED odborn\u00EDk\u016F s podporou CELL, \u010CHS a \u010COS \u010CSL JEP, S.CH.S SLS" . "1212-4184" . "RIV/61989592:15110/11:10224200" . . "hematopoetic stem cell transplantation; acute leukemia; febrile neutropenia; fluoroquinolone; antibacterial profylaxis"@en . "\u0160t\u011Brba, Jaroslav" . . "1"^^ . "Drgo\u0148a, Lubo\u0161" . "[2D37773525B6]" . "Antibiotick\u00E1 profylaxe u hematoonkologick\u00FDch nemocn\u00FDch - doporu\u010Den\u00ED odborn\u00EDk\u016F s podporou CELL, \u010CHS a \u010COS \u010CSL JEP, S.CH.S SLS" . "Cetkovsk\u00FD, Petr" . "15110" . . "Haber, Jan" . . . "I" . "Antibiotick\u00E1 profylaxe u hematoonkologick\u00FDch nemocn\u00FDch - doporu\u010Den\u00ED odborn\u00EDk\u016F s podporou CELL, \u010CHS a \u010COS \u010CSL JEP, S.CH.S SLS"@cs . . "Faber, Edgar" . "\u017D\u00E1k, Pavel" . "186414" . "R\u00E1\u010Dil, Zden\u011Bk" . "Sedl\u00E1\u010Dek, Petr" . "16"^^ . . "Postgradu\u00E1ln\u00ED medic\u00EDna" . . "Antibiotic profylaxis in hematooncological patients - expert recommendation with the support of CELL, CHS and COS CLS JEPO, S.CH.S. SLS"@en . "RIV/61989592:15110/11:10224200!RIV12-MSM-15110___" . "Bakteri\u00E1ln\u00ED infekce jsou nej\u010Dast\u011Bj\u0161\u00ED \u017Eivot ohro\u017Euj\u00EDc\u00ED komplikac\u00ED u nemocn\u00FDch s febriln\u00ED neutropeni\u00ED po protin\u00E1dorov\u00E9 chemoterapii. Jedn\u00EDm z mo\u017En\u00FDch p\u0159\u00EDstup\u016F, jak sn\u00ED\u017Eit riziko bakteri\u00E9mie a \u00FAmrt\u00ED na sepsi v obdob\u00ED neutropenie, je antibakteri\u00E1ln\u00ED profylaxe antibiotiky. Randomizovan\u00E9 klinick\u00E9 studie srovn\u00E1vaj\u00EDc\u00ED profylaxi fluorochinolony proti placebu prok\u00E1zaly efekt profylaxe u nemocn\u00FDch s nejvy\u0161\u0161\u00EDm rizikem vzniku z\u00E1va\u017En\u00FDch infek\u010Dn\u00EDch komplikac\u00ED a \u00FAmrt\u00ED na n\u011B, tj. u nemocn\u00FDch s p\u0159edpokl\u00E1danou dlouhodobou a hlubokou absolutn\u00ED granulocytopeni\u00ED. Metaanal\u00FDzy t\u011Bchto studi\u00ED pak prok\u00E1zaly p\u0159\u00EDzniv\u00FD efekt profylaxe na pokles celkov\u00E9 mortality a mortality na infekci. Na z\u00E1klad\u011B t\u011Bchto studi\u00ED p\u0159edpokl\u00E1d\u00E1 skupina odborn\u00EDk\u016F CELL v kr\u00E1tk\u00E9m souhrnu doporu\u010Den\u00ED profylaxe fluorochinolony a sou\u010Dasn\u011B vyjad\u0159uje nutnost respektovat lok\u00E1n\u00ED epidemiologickou situaci jednotliv\u00FDch pracovi\u0161\u0165 p\u0159i vlastn\u00ED volb\u011B antibakteri\u00E1ln\u00ED profylaxe." . . "CZ - \u010Cesk\u00E1 republika" . . "13" .